logo
La Caisse commits to invest in Sizewell C, a critical asset for economic growth and energy security in the UK

La Caisse commits to invest in Sizewell C, a critical asset for economic growth and energy security in the UK

Globe and Mail22-07-2025
MONTRÉAL and LONDON , July 22, 2025 /CNW/ - Quebec based global investment group, La Caisse (formerly CDPQ), today announces its commitment to invest up to £1.7 billion ( CAD 3.2 billion ) in Sizewell C, a 3.2GW nuclear power station located in the East of England . The investment, which represents a 20% stake in the project, will leverage La Caisse's proven track record in delivering large scale infrastructure projects globally and support the UK's transition to clean power and progress to net zero. Once complete, Sizewell C will provide over 60 years of clean, reliable power to the UK grid, helping to boost the UK's economy, strengthen energy security and help reduce reliance on hydrocarbon sources, avoiding 9 million tonnes of carbon emissions annually.
The investment will be made alongside the UK Government, experienced operator EDF, British multinational energy and services company Centrica and investment partner Amber Infrastructure. The project is structured under the UK Government's Regulated Asset Base (RAB) model which helps fund large-scale projects by offering predictability to investors while ensuring value for consumers over the long term.
"Our commitment to invest in Sizewell C reflects La Caisse's constructive capital approach, working to deliver optimal financial performance for our clients alongside broader economic and societal progress. La Caisse has a strong track record of bringing private sector expertise alongside governments and industrial players to invest in complex, regulated infrastructure where value-for-money for consumers is key. Sizewell C is a positive development for UK consumers, as it is expected to provide long-term reliable baseload power and low carbon energy to more than 6 million homes across the UK, while contributing to the creation of 10,000 new jobs at peak construction and thousands more in the nationwide supply chain. We're proud to support the UK Government in delivering this landmark project, advancing the country's energy security and economic growth ambitions. Our investment demonstrates our confidence in the UK market – our largest destination outside North America – and aligns with our commitment to the energy transition and decarbonization, enabled by our long-term capital and active ownership," said Emmanuel Jaclot, Executive Vice-President and Head of Infrastructure at La Caisse.
"It is time to do big things and build big projects in this country again – and today we announce an investment that will provide clean, homegrown power to millions of homes for generations to come. This government is making the investment needed to deliver a new golden age of nuclear, so we can end delays and free us from the ravages of the global fossil fuel markets to bring bills down for good," said Secretary of State for Energy Security and Net Zero, Ed Miliband.
"We're delighted to welcome La Caisse's investment in Sizewell C. Their decision to take a 20% stake in the project reflects growing international backing for UK nuclear and confidence in Sizewell C. As one of the world's leading institutional investors, La Caisse brings significant experience in sustainable infrastructure and in delivering projects that drive economic growth and long-term value creation. Their involvement reinforces our strong financial base and supports our mission to create tens of thousands of high-quality jobs and 1500 apprenticeships across the country. Sizewell C will boost energy security, cut carbon, and drive regional and national growth for decades to come, and we're proud to have La Caisse on board as part of that journey," said Julia Pyke and Nigel Cann , Joint Managing Directors of Sizewell C.
La Caisse is the world's second largest institutional infrastructure investor, currently manages over £20 billion in UK investments and has significant experience in delivering projects that drive economic growth and positive change. La Caisse intends to invest around £8 billion in the UK over the next five years, increasing its asset allocation to the British market by nearly 50 percent. La Caisse has acted as a partner of trust and choice to the UK Government and its business partners for many years and has brought benefits to millions of UK consumers through investments in Eurostar, Heathrow Airport, First Hydro Company and London Array, an offshore wind farm generating 630MW of electricity, enough to power 500,000 UK homes.
La Caisse is also deeply committed to sustainable investing and investments supporting climate action. The firm has recently committed to have nearly £220 billion ( CAD 400 billion ) invested globally by the end of the decade in companies committed to decarbonising their operations as well as in climate solutions. These investments align with La Caisse's commitment to its clients: delivering long-term value while managing risk responsibly.
ABOUT LA CAISSE
At La Caisse, formerly CDPQ, we have invested for 60 years with a dual mandate: generate optimal long-term returns for our 48 depositors, who represent over 6 million Quebecers, and contribute to Québec's economic development.
As a global investment group, we are active in the major financial markets, private equity, infrastructure, real estate and private credit. As at December 31, 2024, La Caisse's net assets totalled CAD 473 billion. For more information, visit lacaisse.com or consult our LinkedIn or Instagram pages.
For more information
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Best Growth Stocks I'd Buy Right Now
The Best Growth Stocks I'd Buy Right Now

Globe and Mail

time41 minutes ago

  • Globe and Mail

The Best Growth Stocks I'd Buy Right Now

Key Points Intuitive Surgical continues to lead the way in robotic surgical instruments. Restaurant chain Cava Group is making strides where some rivals are faltering. 10 stocks we like better than Intuitive Surgical › If you're a growth-oriented investor like me, you've probably seen your portfolio experience its fair share of ups and downs the last few years. While the market has rebounded to new heights and many growth businesses have recovered spectacularly, results have varied by individual stock. As always, it's important to look beyond a stock's price and see what's happening behind the scenes. A share price may be up or down for a good reason, but you need to understand the factors driving these movements before you hit the buy button. On that note, here are two top growth stocks to consider if you have cash to invest right now. 1. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) has been known for its pioneering role in robotic-assisted surgery with the da Vinci surgical system since its first platform was approved more than two decades ago. The da Vinci system provides surgeons with enhanced dexterity, precision, and control during minimally invasive procedures including thoracic, gynecologic, and general surgeries. These systems allow for a wider range of motion than the human hand and wrist, translating surgeon movements into precise instrument actions within a patient's body. This is particularly helpful for complex procedures in confined spaces, but can also improve surgery outcomes, shorten recovery time, and reduce the risk of adverse complications. Intuitive Surgical's revenue comes from three different sources: system sales, instruments and accessories, and services. What might be surprising is that Intuitive's most significant revenue stream is selling instruments and accessories such as forceps, scissors, scalpels, drapes, and vision products. Once a da Vinci system is installed in a hospital, each surgery performed using that system requires these specialized instruments and accessories, many of which are single-use or need to be replaced after a set number of uses. Of course, as systems can cost $1 million or more apiece, one-time sales, as well as usage-based or lease-type sales of systems, are a key driver of revenue. Finally, the services business encompasses the comprehensive support provided to customers, including installation, maintenance, and repair of surgical systems. Intuitive typically includes service contracts with the initial sale of a da Vinci system, providing ongoing revenue through annual fees. These contracts can vary in price depending on the system configuration and the scope of services included. The company's new da Vinci 5 platform is now broadly available in the U.S., and limited launches are starting in Europe and Japan after receiving the necessary regulatory clearances. The da Vinci 5 system has been well-received so far, with over 100,000 procedures already performed since its initial approval in the U.S. in early 2024. Intuitive Surgical's revenue growth for the first half of 2025 totaled $4.69 billion, a healthy 20% increase from the $3.9 billion it reported in the first half of 2024. Net income for the first six months of 2025 came to $1.4 billion, up 27% on a year-over-year basis. And the average consensus 12-month price target from analysts suggests a potential upside of approximately 20% from current share prices. If you're a long-term investor who wants a piece of the action of a top-notch healthcare stock, definitely consider Intuitive Surgical. 2. Cava Group Cava Group (NYSE: CAVA) is a fast-casual Mediterranean restaurant chain that offers customizable bowls, salads, and pitas with a focus on fresh, healthy ingredients. The company also produces and sells a line of Mediterranean dips, spreads, and dressings available in grocery stores. Cava has been a standout example of a fast-casual restaurant that's expanding gradually and strategically without sacrificing its financial health. In fact, Cava's financials keep looking better and better. Revenue reached $329 million in the first quarter of its fiscal 2025, a 28% increase compared to the same period last year. Same-store sales also increased by 10.8% in Q1, while Cava opened 15 new restaurants in the three-month period alone. That rate of expansion brought its restaurant total to 382 locations across 26 states and the District of Columbia. The company is also building a consistent track record of profitability. Its Q1 net income of nearly $26 million was almost double that of the previous year. And Cava is targeting 1,000 restaurants by 2032, a significant expansion of its current footprint. Importantly, restaurant-level profit of $82.3 million was up 27.4% in Q1 on a year-over-year basis, and restaurant-level profit margin was 25.1%. These are impressive figures for a fast-casual restaurant that's still in the relatively early stages of its growth story. Cava has shown resilience in navigating macroeconomic headwinds by focusing on strategic pricing, guest engagement, and operational excellence. The restaurant stock seems to be resonating with consumers, providing a strong value proposition in a sector of the restaurant industry that's highly competitive and fragmented. If you have the risk appetite to invest in a business operating in a more cyclical consumer-facing space, Cava looks like a quality buy to consider right now. Should you invest $1,000 in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025

TELUS Reports Q2 2025 Growth and Strategic Infrastructure Sale
TELUS Reports Q2 2025 Growth and Strategic Infrastructure Sale

Globe and Mail

time2 hours ago

  • Globe and Mail

TELUS Reports Q2 2025 Growth and Strategic Infrastructure Sale

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Telus ( (TSE:T)) has shared an announcement. On August 1, 2025, TELUS Corporation announced its second-quarter 2025 financial results, highlighting a 2% increase in consolidated operating revenues to $5.1 billion, driven by strong customer growth in its mobile and fixed services. The company reported an 11% rise in free cash flow and reaffirmed its financial targets for 2025. TELUS also announced a significant transaction with La Caisse, selling a 49.9% stake in its wireless tower infrastructure operator Terrion for $1.26 billion, which is expected to aid in reducing its leverage ratio. Despite recognizing a $500 million impairment related to TELUS Digital, the company remains focused on sustainable growth and enhancing shareholder value. The most recent analyst rating on (TSE:T) stock is a Buy with a C$24.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page. Spark's Take on TSE:T Stock According to Spark, TipRanks' AI Analyst, TSE:T is a Neutral. Telus exhibits strong financial performance with effective cost management and cash flow generation. The technical analysis suggests stable market conditions, while the high dividend yield adds attractiveness despite a higher P/E ratio. Positive corporate events further enhance Telus's financial strategy and market standing. To see Spark's full report on TSE:T stock, click here. More about Telus TELUS Corporation is a leading Canadian telecommunications company that provides a wide range of telecommunications products and services including mobile and fixed-line services, internet, and television. The company is also heavily invested in health technology through its TELUS Health segment, and it focuses on expanding its PureFibre connectivity across Canada. Average Trading Volume: 3,512,550 Technical Sentiment Signal: Strong Buy Current Market Cap: C$34.04B Learn more about T stock on TipRanks' Stock Analysis page.

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today

Globe and Mail

time2 hours ago

  • Globe and Mail

If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today

Key Points If you'd invested in AbbVie 10 years ago, you would likely be pleased. The drugmaker has paid and grown its dividend quite well over this period. Its two immunosuppressants, Skyrizi and Rinvoq, have seen expanding sales. 10 stocks we like better than AbbVie › Think back to 10 years ago. The New England Patriots and their quarterback Tom Brady were accused of underinflating footballs. The Supreme Court affirmed same-sex marriage nationwide. And Apple introduced its Apple Watch. Also, as happens in every year, many investors bought stocks. What if you'd spent $1,000 on shares of AbbVie (NYSE: ABBV) stock a decade ago? What would that stake be worth now? It would be worth $3,350 -- or, if you'd reinvested your dividends in additional shares of AbbVie stock, it would be worth $4,105. That's because AbbVie is a solid dividend payer, with a recent dividend yield of 3.4%. It's a dividend grower, too. Its total annual payout was recently $6.47 per share, up from $5.64 in 2022 and $3.59 in 2018. Before you kick yourself about missing out on this investment, know that it was actually close to average, with dividends not reinvested. AbbVie's average annual gain was 12.84%, compared to 12.62% for the S&P 500 index. When you reinvest dividends for both, AbbVie is more clearly ahead, 15.17% vs. 13.59%. AbbVie was spun off from Abbott Laboratories in 2013, and it's a major global pharmaceutical company with a recent market value topping $330 billion. The company is known for treatments in the fields of immunology, oncology, aesthetics, neuroscience, and eye care. A downside for investors is that it lost patent protection for its blockbuster drug Humira -- but it has a promising pipeline of drugs in development, and two immunosuppressants, Skyrizi and Rinvoq, have been selling well. It's not too late to invest in AbbVie if you like what you see with the company. At recent levels, the stock seems neither wildly overvalued nor undervalued. Its recent price-to-sales ratio of 5.9 is a bit above its five-year average of 4.7, but that's not necessarily a deal-breaker for long-term investors. Perhaps in 2035, you'll be looking back and smiling. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store